The importance of the β-cell in the pathogenesis of type 2 diabetes mellitus

American Journal of Medicine

Volumn 108, Issue 6 SUPPL. 1, 2000, Pages 2-8

  Kahn, Steven E ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLIN; GLUCOSE; IMMUNOREACTIVE INSULIN; INSULIN; PROINSULIN;

CONFERENCE PAPER; DISEASE COURSE; ETHNIC GROUP; GLUCOSE TOLERANCE TEST; HUMAN; HYPERGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN METABOLISM; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PANCREAS ISLET BETA CELL; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RADIOIMMUNOASSAY;

EID: 0034678739     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0002-9343(00)00336-3     Document Type: Conference Paper

References (31)

1. Kahn SE, Porte D Jr. The pathophysiology of type II (noninsulin-dependent) diabetes mellitus: Implications for treatment. In: Porte D Jr, Sherwin RS, eds. Diabetes Mellitus. New York: Elsevier, 1996:487-512.
2. Yalow R.S., Berson S.A. Immunoassay of endogenous plasma insulin in man. J Clin Invest. 39:1960;1157-1175.
3. Bagdade J.D., Bierman E.L., Porte D. Jr. The significance of basal insulin levels in the evaluation of the insulin response to glucose in diabetic and nondiabetic subjects. J Clin Invest. 46:1967;1549-1557.
4. Ward W.K., Beard J.C., Halter J.B., Pfeifer M.A., Porte D. Jr. Pathophysiology of insulin secretion in non-insulin-dependent diabetes mellitus. Diabetes Care. 7:1984;491-502.
5. Polonsky K.S., Sturis J., Bell G.I. Non-insulin-dependent diabetes mellitus - a genetically programmed failure of the β cell to compensate for insulin resistance. N Engl J Med. 334:1996;777-783.
6. Kahn S.E. Regulation of β-cell function in vivo from health to disease . Diabetes Rev. 4:1996;372-389.
7. Kahn S.E., Prigeon R.L., McCulloch D.K., et al. Quantification of the relationship between insulin sensitivity and β-cell function in human subjects evidence for a hyperbolic function . Diabetes. 42:1993;1663-1672.
8. Pfeifer M.A., Halter J.B., Porte D. Jr. Insulin secretion in diabetes mellitus. Am J Med. 70:1981;579-588.
9. Kahn S.E., Verchere C.B., Andrikopoulos S., et al. Reduced amylin release is a characteristic of impaired glucose tolerance and type 2 diabetes in Japanese Americans. Diabetes. 47:1998;640-645.
10. Ward W.K., LaCava E.C., Paquette T.L., et al. Disproportionate elevation of immunoreactive proinsulin in type 2 (non-insulin-dependent) diabetes mellitus and in experimental insulin resistance. Diabetologia. 30:1987;698-702.
11. Saad M.F., Kahn S.E., Nelson R.G., et al. Disproportionately elevated proinsulin in Pima Indians with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 70:1990;1247-1253.
12. Kahn S.E., Halban P.A. Release of incompletely processed proinsulin is the cause of the disproportionate proinsulinemia of NIDDM. Diabetes. 46:1997;1725-1732.
13. Yoshioka N., Kuzuya T., Matsuda A., et al. Serum proinsulin levels at fasting and after oral glucose load in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia. 31:1988;355-360.
14. Temple R.C., Carrington C.A., Luzio S.D., et al. Insulin deficiency in non-insulin-dependent diabetes. Lancet. 1:1989;293-295.
15. Haffner S.M., Mykkanen L., Stern M.P., et al. Relationship of proinsulin and insulin to cardiovascular risk factors in nondiabetic subjects. Diabetes. 42:1993;1297-1302.
16. Kahn S.E., Leonetti D.L., Prigeon R.L., et al. Proinsulin as a marker for the development of NIDDM in Japanese-American men. Diabetes. 44:1995;173-179.
17. Roder M.E., Porte D. Jr, Schwartz R.S., Kahn S.E. Disproportionately elevated proinsulin levels reflect the degree of impaired β cell secretory capacity in patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 83:1998;604-608.
18. Mykkänen L., Haffner S.M., Kuusisto J., et al. Serum proinsulin levels are disproportionately increased in elderly prediabetic subjects. Diabetologia. 38:1995;1176-1182.
19. Yki-Järvinen H. Glucose toxicity. Endocrinol Rev. 13:1992;415-431.
20. Unger R.H. Lipotoxicity in the pathogenesis of obesity-dependent NIDDM genetic and clinical implications . Diabetes. 44:1995;863-870.
21. Opie E. The relation of diabetes mellitus to lesions of the pancreas. Hyaline degeneration of the islands of Langerhans. J Exp Med. 5:1901;527-540.
22. Westermark P., Wilander E. The influence of amyloid deposits on the islet volume in maturity onset diabetes mellitus. Diabetologia. 15:1978;417-421.
23. Westermark P. Amyloid and polypeptide hormones what is their relationship? Amyloid: Int J Exp Clin Invest. 1:1994;47-60.
24. Westermark P., Wernstedt C., Wilander E., et al. Amyloid fibrils in human insulinoma and islets of Langerhans of the diabetic cat are derived from a neuropeptide-like protein also present in normal islets. Proc Natl Acad Sci USA. 84:1987;3881-3885.
25. Cooper G.J.S., Willis A.C., Clark A., et al. Purification and characterization of a peptide from arnyloid-rich pancreases of type 2 diabetic patients. Proc Natl Acad Sci USA. 84:1987;8628-8632.
26. Enoki S., Mitsukawa T., Takemura J., et al. Plasma islet amyloid polypeptide levels in obesity, impaired glucose tolerance and non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract. 15:1992;97-102.
27. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 352:1998;837-853.
28. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 352:1998;854-865.
29. Turner R.C., Cull C.A., Frighi V., Holman R.R. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus progressive requirement for multiple therapies (UKPDS 49) . JAMA. 281:1999;2005-2012.
30. Matthews D.R., Cull C.A., Stratton I.M., et al. for the UK Prospective Diabetes Study (UKPDS) Group. UKPDS 26: sulfonylurea failure in non-insulin-dependent diabetic patients over six years. Diabet Med. 15:1998;297-303.
31. Weyer C., Bogardus C., Mott D.M., Pratley R.E. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest. 104:1999;787-794.